Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 905,041
  • Shares Outstanding, K 283,712
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,650 K
  • EBIT $ -144 M
  • EBITDA $ -150 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.36

Options Overview Details

View History
  • Implied Volatility 182.67% (-14.90%)
  • Historical Volatility 75.42%
  • IV Percentile 36%
  • IV Rank 11.80%
  • IV High 1,077.61% on 04/10/25
  • IV Low 62.89% on 12/18/24
  • Expected Move (DTE 14) 0.77 (23.98%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 4,962
  • Volume Avg (30-Day) 938
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 54,268
  • Open Int (30-Day) 54,519
  • Expected Range 2.43 to 3.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.11
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +51.54%
on 11/07/25
3.38 -5.48%
on 12/03/25
+0.88 (+38.10%)
since 11/04/25
3-Month
1.47 +117.01%
on 09/05/25
3.38 -5.48%
on 12/03/25
+1.71 (+115.54%)
since 09/04/25
52-Week
1.01 +215.84%
on 04/09/25
3.38 -5.48%
on 12/03/25
+0.06 (+1.92%)
since 12/04/24

Most Recent Stories

More News
Erasca to Present at the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 3.19 (-3.04%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9807 (+8.19%)
IMRX : 6.69 (-0.74%)
ALXO : 1.3700 (+3.79%)
ERAS : 3.19 (-3.04%)
PRLD : 1.5400 (+11.59%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9807 (+8.19%)
IMRX : 6.69 (-0.74%)
ALXO : 1.3700 (+3.79%)
ERAS : 3.19 (-3.04%)
PRLD : 1.5400 (+11.59%)
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043  Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001...

ERAS : 3.19 (-3.04%)
Erasca to Present at Upcoming Conferences in November

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 3.19 (-3.04%)
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 3.19 (-3.04%)
Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust...

ERAS : 3.19 (-3.04%)
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

/CNW/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline....

ONCY : 0.9807 (+8.19%)
CLRB : 3.80 (+2.98%)
INTS : 0.4603 (+12.32%)
ARAY : 1.0200 (-0.97%)
ONC.TO : 1.42 (+2.16%)
ERAS : 3.19 (-3.04%)
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

ERAS : 3.19 (-3.04%)
Erasca to Present at Upcoming Investor Conferences in June

ERAS : 3.19 (-3.04%)

Business Summary

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 3.49
2nd Resistance Point 3.42
1st Resistance Point 3.31
Last Price 3.19
1st Support Level 3.12
2nd Support Level 3.05
3rd Support Level 2.94

See More

52-Week High 3.38
Last Price 3.19
Fibonacci 61.8% 2.47
Fibonacci 50% 2.19
Fibonacci 38.2% 1.91
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar